EA010924B1 - Способ получения партий рекомбинантного аденовируса и используемые для этого пакующие клетки - Google Patents
Способ получения партий рекомбинантного аденовируса и используемые для этого пакующие клетки Download PDFInfo
- Publication number
- EA010924B1 EA010924B1 EA200600693A EA200600693A EA010924B1 EA 010924 B1 EA010924 B1 EA 010924B1 EA 200600693 A EA200600693 A EA 200600693A EA 200600693 A EA200600693 A EA 200600693A EA 010924 B1 EA010924 B1 EA 010924B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sequences
- cells
- cell
- genome
- fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 241000701161 unidentified adenovirus Species 0.000 title claims description 72
- 238000004806 packaging method and process Methods 0.000 title abstract description 37
- 239000013598 vector Substances 0.000 claims abstract description 64
- 239000002245 particle Substances 0.000 claims abstract description 23
- 230000001419 dependent effect Effects 0.000 claims abstract description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 52
- 108020004707 nucleic acids Proteins 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 45
- 101710114676 E1B 55 kDa protein Proteins 0.000 claims description 28
- 108091026890 Coding region Proteins 0.000 claims description 25
- 101710175001 E1B protein, small T-antigen Proteins 0.000 claims description 24
- 230000015572 biosynthetic process Effects 0.000 claims description 23
- 238000012217 deletion Methods 0.000 claims description 16
- 230000037430 deletion Effects 0.000 claims description 16
- 239000002243 precursor Substances 0.000 claims description 15
- 230000008488 polyadenylation Effects 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 271
- 239000012634 fragment Substances 0.000 description 114
- 108020004414 DNA Proteins 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 45
- 239000013612 plasmid Substances 0.000 description 44
- 239000000499 gel Substances 0.000 description 33
- 239000002773 nucleotide Substances 0.000 description 30
- 125000003729 nucleotide group Chemical group 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 24
- 238000001890 transfection Methods 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 21
- 230000010354 integration Effects 0.000 description 21
- 241000700605 Viruses Species 0.000 description 20
- 230000001105 regulatory effect Effects 0.000 description 19
- 238000012856 packing Methods 0.000 description 18
- 238000000605 extraction Methods 0.000 description 16
- 210000000349 chromosome Anatomy 0.000 description 14
- 238000002744 homologous recombination Methods 0.000 description 14
- 239000011543 agarose gel Substances 0.000 description 13
- 238000010276 construction Methods 0.000 description 13
- 230000006801 homologous recombination Effects 0.000 description 13
- 125000006850 spacer group Chemical group 0.000 description 13
- 230000009466 transformation Effects 0.000 description 13
- 238000013461 design Methods 0.000 description 12
- 210000005260 human cell Anatomy 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 238000003780 insertion Methods 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 238000010367 cloning Methods 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 101150075174 E1B gene Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- -1 spacer nucleic acids Chemical class 0.000 description 5
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 101710199711 Early E1A protein Proteins 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 210000001776 amniocyte Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 239000013601 cosmid vector Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 2
- 101001027192 Homo sapiens Kelch-like protein 41 Proteins 0.000 description 2
- 101150092727 KLF10 gene Proteins 0.000 description 2
- 102100037644 Kelch-like protein 41 Human genes 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 240000005499 Sasa Species 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 241000208140 Acer Species 0.000 description 1
- 102000005869 Activating Transcription Factors Human genes 0.000 description 1
- 108010005254 Activating Transcription Factors Proteins 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 101001035782 Gallus gallus Hemoglobin subunit beta Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 101100234645 Mus musculus Krt36 gene Proteins 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
- 206010044625 Trichorrhexis Diseases 0.000 description 1
- 101100108191 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) add gene Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 101000872823 Xenopus laevis Probable histone deacetylase 1-A Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108700019031 adenovirus E1B55K Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 108010086721 apolipoprotein E1 Proteins 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 101150054175 cro gene Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000006740 morphological transformation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- AKUNSPZHHSNFFX-UHFFFAOYSA-M tributyl(tetradecyl)phosphanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[P+](CCCC)(CCCC)CCCC AKUNSPZHHSNFFX-UHFFFAOYSA-M 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0350679 | 2003-10-02 | ||
| PCT/EP2004/052428 WO2005033320A1 (en) | 2003-10-02 | 2004-10-04 | Packaging cells for recombinant adenovirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200600693A1 EA200600693A1 (ru) | 2006-10-27 |
| EA010924B1 true EA010924B1 (ru) | 2008-12-30 |
Family
ID=34400432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200600693A EA010924B1 (ru) | 2003-10-02 | 2004-10-04 | Способ получения партий рекомбинантного аденовируса и используемые для этого пакующие клетки |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7816104B2 (enExample) |
| EP (1) | EP1670925B1 (enExample) |
| JP (1) | JP4749334B2 (enExample) |
| KR (1) | KR101203817B1 (enExample) |
| CN (2) | CN1863918B (enExample) |
| AU (1) | AU2004278517B2 (enExample) |
| BR (1) | BRPI0414670A (enExample) |
| CA (1) | CA2538025C (enExample) |
| DK (1) | DK1670925T3 (enExample) |
| EA (1) | EA010924B1 (enExample) |
| HR (1) | HRP20130616T1 (enExample) |
| IL (2) | IL174489A (enExample) |
| NZ (1) | NZ545501A (enExample) |
| SI (1) | SI1670925T1 (enExample) |
| WO (1) | WO2005033320A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| EP1670925B1 (en) | 2003-10-02 | 2013-05-01 | Crucell Holland B.V. | Packaging cells for recombinant adenovirus |
| EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| WO2008134720A2 (en) * | 2007-04-30 | 2008-11-06 | Medtronic, Inc. | Inert dna sequences for efficient viral packaging and methods of use |
| CA2742474C (en) | 2008-11-03 | 2016-05-31 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
| KR101427200B1 (ko) * | 2011-11-24 | 2014-08-07 | 주식회사 바이로메드 | 아데노바이러스 생산 신규 세포주 및 그의 용도 |
| MY170927A (en) | 2011-11-28 | 2019-09-19 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| AP2014007993A0 (en) * | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against RSV |
| CN110832072B (zh) | 2017-04-21 | 2023-11-07 | 真基因太科公司 | 用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法 |
| CN108342362A (zh) * | 2018-01-31 | 2018-07-31 | 武汉枢密脑科学技术有限公司 | 一种用于扩增重组犬腺病毒cav2的稳定细胞系mdck及其构建方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994128A (en) * | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| WO2002040665A2 (en) * | 2000-11-15 | 2002-05-23 | Crucell Holland B.V. | Complementing cell lines |
| WO2003031633A2 (de) * | 2001-10-04 | 2003-04-17 | Probiogen Ag | Adenovirales vektorsystem |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889806A (en) * | 1987-04-15 | 1989-12-26 | Washington University | Large DNA cloning system based on yeast artificial chromosomes |
| US5610053A (en) | 1993-04-07 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5820868A (en) | 1993-12-09 | 1998-10-13 | Veterinary Infectious Disease Organization | Recombinant protein production in bovine adenovirus expression vector system |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| FI972225A7 (fi) | 1994-11-28 | 1997-07-16 | Genetic Therapy Inc | Vektorit kudosspesifistä replikaatiota varten |
| CA2206683A1 (en) | 1994-12-12 | 1996-06-20 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
| ATE289354T1 (de) | 1999-04-15 | 2005-03-15 | Crucell Holland Bv | Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen. |
| US6558948B1 (en) | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
| EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| CA2812799C (en) | 2001-07-04 | 2016-01-26 | Chromagenics B.V. | Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using such dna sequences |
| US7026164B2 (en) | 2003-07-03 | 2006-04-11 | Cell Genesys, Inc. | Adenovirus packaging cell lines |
| EP1670925B1 (en) | 2003-10-02 | 2013-05-01 | Crucell Holland B.V. | Packaging cells for recombinant adenovirus |
-
2004
- 2004-10-04 EP EP04791140.9A patent/EP1670925B1/en not_active Expired - Lifetime
- 2004-10-04 BR BRPI0414670-0A patent/BRPI0414670A/pt not_active Application Discontinuation
- 2004-10-04 WO PCT/EP2004/052428 patent/WO2005033320A1/en not_active Ceased
- 2004-10-04 CA CA2538025A patent/CA2538025C/en not_active Expired - Fee Related
- 2004-10-04 AU AU2004278517A patent/AU2004278517B2/en not_active Ceased
- 2004-10-04 JP JP2006530273A patent/JP4749334B2/ja not_active Expired - Fee Related
- 2004-10-04 DK DK04791140.9T patent/DK1670925T3/da active
- 2004-10-04 CN CN2004800286959A patent/CN1863918B/zh not_active Expired - Fee Related
- 2004-10-04 SI SI200432052T patent/SI1670925T1/sl unknown
- 2004-10-04 KR KR1020067006263A patent/KR101203817B1/ko not_active Expired - Fee Related
- 2004-10-04 CN CN2011100542020A patent/CN102174536B/zh not_active Expired - Fee Related
- 2004-10-04 EA EA200600693A patent/EA010924B1/ru not_active IP Right Cessation
- 2004-10-04 NZ NZ545501A patent/NZ545501A/en not_active IP Right Cessation
- 2004-10-04 HR HRP20130616TT patent/HRP20130616T1/hr unknown
-
2006
- 2006-03-20 US US11/384,850 patent/US7816104B2/en not_active Expired - Fee Related
- 2006-03-22 IL IL174489A patent/IL174489A/en active IP Right Grant
-
2010
- 2010-07-14 US US12/804,179 patent/US8114637B2/en not_active Expired - Fee Related
-
2013
- 2013-07-18 IL IL227543A patent/IL227543A/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994128A (en) * | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| WO2002040665A2 (en) * | 2000-11-15 | 2002-05-23 | Crucell Holland B.V. | Complementing cell lines |
| WO2003031633A2 (de) * | 2001-10-04 | 2003-04-17 | Probiogen Ag | Adenovirales vektorsystem |
Non-Patent Citations (7)
| Title |
|---|
| FALLAUX F. ET AL.: "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses", HUMAN GENE THERAPY, XX, XX, vol. 9, no. 9, 1 September 1998 (1998-09-01), pages 1909-1917, XP002111070 ISSN: 1043-0342 * |
| GALLIMORE P. H. ET AL.: "TRANSFORMATION OF HUMAN EMBRYO RETINOBLASTS WITH SIMIAN VIRUS 40, ADENOVIRUS AND RAS ONCOGENES", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS, GR, vol. 6, no. 3, May 1986 (1986-05), pages 499-508, XP008020458 ISSN: 0250-7005 * |
| IMLER J-L ET AL.: "NOVEL COMPLEMENTATION CELL LNES DERIVED FROM HUMAN LUNG CARCINOMA A549 CELLS SUPPORT THE GROWTH OF E1-DELETED ADENOVIRUS VECTORS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 3, no. 1, 1996, pages 75-84, XP000990623 ISSN: 0969-7128, the whole document * |
| JOCHEMSEN A. G. ET AL.: "ACTIVATION OF ADENOVIRUS 5 E1A TRANSCRIPTION BY REGION E1B IN TRANSFORMED PRIMARY RAT CELLS", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 6, no. 11, 1987, pages 3399-3406, XP009030196 ISSN: 0261-4189 * |
| LOCHMUELLER H. ET AL.: "Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (detaEl + deltaE3) during multiple passages in 293 cells", HUMAN GENE THERAPY, XX, XX, vol. 5, Decembur 1994 (1994-12), pages 1485-1491, XP008972681 ISSN: 1043-0342, the whole document * |
| MURAKAMI PETE ET AL.: "A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles", HUMAN GENE THERAPY, vol. 13, no. 8, 20 May 2002 (2002-05-20), pages 909-920, XP002278921 ISSN: 1043-0342 * |
| VAN DEN ELSEN P. ET AL.: "THE RELATIONSHIP BETWEEN REGION E-1A AND E-1B OF HUMAN ADENOVIRUSES IN CELL TRANSFORMATION", GENE (AMSTERDAM), vol. 18, no. 2, 1982, pages 175-186, XP001181139 ISSN: 0378-1119, the whole document * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100311172A1 (en) | 2010-12-09 |
| IL174489A (en) | 2013-10-31 |
| CN102174536B (zh) | 2013-02-13 |
| CN1863918A (zh) | 2006-11-15 |
| AU2004278517A1 (en) | 2005-04-14 |
| HRP20130616T1 (en) | 2013-08-31 |
| CN102174536A (zh) | 2011-09-07 |
| BRPI0414670A (pt) | 2006-11-21 |
| CN1863918B (zh) | 2011-03-30 |
| US20060183232A1 (en) | 2006-08-17 |
| IL227543A (en) | 2015-08-31 |
| HK1084974A1 (en) | 2006-08-11 |
| KR20060095557A (ko) | 2006-08-31 |
| CA2538025A1 (en) | 2005-04-14 |
| IL174489A0 (en) | 2006-08-01 |
| EP1670925A1 (en) | 2006-06-21 |
| AU2004278517B2 (en) | 2010-04-01 |
| KR101203817B1 (ko) | 2012-11-23 |
| DK1670925T3 (da) | 2013-07-08 |
| EP1670925B1 (en) | 2013-05-01 |
| US8114637B2 (en) | 2012-02-14 |
| SI1670925T1 (sl) | 2013-10-30 |
| NZ545501A (en) | 2010-12-24 |
| JP4749334B2 (ja) | 2011-08-17 |
| WO2005033320A1 (en) | 2005-04-14 |
| CA2538025C (en) | 2012-07-17 |
| US7816104B2 (en) | 2010-10-19 |
| EA200600693A1 (ru) | 2006-10-27 |
| JP2007507216A (ja) | 2007-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017257225B2 (en) | Allele editing and applications thereof | |
| ES2258265T3 (es) | Vectores de replicacion con especificidad tisular. | |
| CN107828738A (zh) | 一种dna甲基转移酶缺陷型cho细胞系及其制备方法及应用 | |
| WO2017054647A1 (zh) | 一种高效安全的转座子整合系统及其用途 | |
| US11795475B2 (en) | Cell strain for reducing production of replication competent adenovirus, and construction method and use thereof | |
| EA010924B1 (ru) | Способ получения партий рекомбинантного аденовируса и используемые для этого пакующие клетки | |
| CN110616199A (zh) | 一种复制缺陷型重组人7型腺病毒及其制备方法和应用 | |
| CN112921072A (zh) | 一种脑转移相关基因的CRISPR/Cas9文库高通量筛选方法 | |
| Doerfler | Adenoviruses | |
| CN108384763B (zh) | 一种传染性脾肾坏死病毒orf074基因缺失株及其制备方法和应用 | |
| CN109837301B (zh) | 人源化幽门螺旋杆菌cagA真核表达载体构建方法 | |
| CN113699122B (zh) | 一种多基因融合溶瘤腺病毒及其构建方法和应用 | |
| Wong et al. | Production of double-stranded DNA ministrings | |
| Jetzer et al. | Engineered human adenoviruses of species B and C report early, intermediate early, and late viral gene expression | |
| Klessig | Adenovirus—Simian Virus 40 Interactions | |
| CN101838310B (zh) | 碱性成纤维细胞生长因子抗原表位模拟肽t3及其应用 | |
| CN117431272A (zh) | 一种在鸡原代肌内脂肪细胞中稳定过表达的cx3cl1慢病毒重组载体的构建方法及应用 | |
| CN108220252B (zh) | 一种传染性脾肾坏死病毒orf022基因缺失株及其制备方法和应用 | |
| JP5260815B2 (ja) | 組換えアデノウイルスおよびアデノウイルスライブラリーの調製 | |
| CN116286911A (zh) | 一种响应缺氧环境调控病毒复制的可剪接系统及其用途 | |
| CN108384764B (zh) | 一种传染性脾肾坏死病毒orf069基因缺失株及其制备方法和应用 | |
| CN119144603A (zh) | 靶向敲除hla-g异构体基因的基因编辑系统和应用 | |
| Heyn et al. | Self-Repairing Herpesvirus Saimiri Deletion Variants | |
| CN113846166B (zh) | 用于检测肝癌的生物标志物及其应用 | |
| CN113238053B (zh) | 一种用于检测stat3二聚化的质粒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |